Literature DB >> 18490799

Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea.

M P Bauer1, A Goorhuis, T Koster, S C Numan-Ruberg, E C Hagen, S B Debast, E J Kuijper, J T van Dissel.   

Abstract

The emergence of hypervirulent strains of Clostridium difficile causing outbreaks in hospitals and nursing homes may result in a greater than before spread of the bacterium in the community. By consequence, the incidence of community-onset cases of Clostridium difficile-associated diarrhoea (CDAD) may increase outside known risk groups that are currently characterised by prior hospitalisation, prior antibiotic usage, older age and significant comorbidity. Here, we describe two case histories of community-onset CDAD. The first concerns a previously healthy young female with community-acquired CDAD without recent hospitalisation or antibiotic usage. The second patient developed diarrhoea in the community after discharge from a hospital where--in retrospect--an outbreak of CDAD occurred. The cases illustrate that CDAD should be included in the differential diagnosis of patients seeking care for community-onset diarrhoea, even in those without characteristic risk factors for CDAD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490799

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  20 in total

1.  Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Authors:  Daniel E Freedberg; Julian A Abrams
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

2.  Spectrum of Clostridium difficile infections outside health care facilities.

Authors:  Ed J Kuijper; Jaap T van Dissel
Journal:  CMAJ       Date:  2008-10-07       Impact factor: 8.262

3.  Prevalence and genotypic characteristics of Clostridium difficile in a closed and integrated human and swine population.

Authors:  Keri N Norman; H Morgan Scott; Roger B Harvey; Bo Norby; Michael E Hume; Kathleen Andrews
Journal:  Appl Environ Microbiol       Date:  2011-07-01       Impact factor: 4.792

4.  Toxic megacolon from hypervirulent Clostridium difficile infection (ribotype 027) following elective total knee replacement: an emerging challenge in modern health care.

Authors:  Buchi Rajendra Babu Arumilli; Prasanthi Koneru; Irfan Fayyaz
Journal:  BMJ Case Rep       Date:  2010-01-13

5.  Repurposing the Antiamoebic Drug Diiodohydroxyquinoline for Treatment of Clostridioides difficile Infections.

Authors:  Nader S Abutaleb; Mohamed N Seleem
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

6.  Prevalence and clinical course of Clostridium difficile infection in a tertiary-care hospital: a retrospective analysis.

Authors:  Meghraj Ingle; Abhijit Deshmukh; Devendra Desai; Philip Abraham; Anand Joshi; Camilla Rodrigues; Ranjit Mankeshwar
Journal:  Indian J Gastroenterol       Date:  2011-05-07

7.  Outcomes in community-acquired Clostridium difficile infection.

Authors:  S Khanna; D S Pardi; S L Aronson; P P Kammer; L M Baddour
Journal:  Aliment Pharmacol Ther       Date:  2012-01-10       Impact factor: 8.171

8.  Clostridium difficile as a cause of acute diarrhea: a prospective study in a tertiary care center.

Authors:  Meghraj Ingle; Abhijit Deshmukh; Devendra Desai; Philip Abraham; Anand Joshi; Tarun Gupta; Camilla Rodrigues
Journal:  Indian J Gastroenterol       Date:  2013-03-24

9.  Clostridium difficile: a new zoonotic agent?

Authors:  Alexander Indra; Heimo Lassnig; Nina Baliko; Peter Much; Anita Fiedler; Steliana Huhulescu; Franz Allerberger
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

10.  High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.

Authors:  A Wadhwa; M F Al Nahhas; R A Dierkhising; R Patel; P Kashyap; D S Pardi; S Khanna; M Grover
Journal:  Aliment Pharmacol Ther       Date:  2016-07-22       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.